Payment overview · 2025
General Payments
$549.94
27 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Ryan Vaclaw, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BARTLESVILLE, OK · NPI 1942295308
Verified facts
What the public records show
CMS Open Payments records show Michael Ryan Vaclaw, M.D. received $549.94 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $129.35 | 23.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $111.21 | 20.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.79 | 17.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.25 | 11.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.52 | 11.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.99 | 8.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.17 | 2.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.16 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.50 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.94 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $111.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.65 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.00 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $95.79 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.52 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.52 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
266 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 636 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 527 | 114 |
| Furosemide | Furosemide | 478 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 426 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 104 |
| Lisinopril | Lisinopril | 381 | 97 |
| Gabapentin | Gabapentin | 360 | 68 |
| Potassium Chloride | Potassium Chloride | 323 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 314 | 57 |
| Metformin Hcl | Metformin Hcl | 295 | 68 |
| Losartan Potassium | Losartan Potassium | 270 | 71 |
| Eliquis | Apixaban | 266 | 33 |
| Simvastatin | Simvastatin | 262 | 69 |
| Omeprazole | Omeprazole | 247 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 231 | 64 |
| Trazodone Hcl | Trazodone Hcl | 203 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 47 |
| Famotidine | Famotidine | 182 | 26 |
| Spironolactone | Spironolactone | 177 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 176 | 37 |
| Sertraline Hcl | Sertraline Hcl | 175 | 38 |
| Meloxicam | Meloxicam | 170 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 150 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 25 |
| Carvedilol | Carvedilol | 129 | 22 |
| Memantine Hcl | Memantine Hcl | 122 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 120 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 43 |
| Xarelto | Rivaroxaban | 111 | 14 |
| Donepezil Hcl | Donepezil Hcl | 110 | 18 |
| Baclofen | Baclofen | 102 | 20 |
| Mirtazapine | Mirtazapine | 102 | 18 |
| Montelukast Sodium | Montelukast Sodium | 102 | 22 |
| Buspirone Hcl | Buspirone Hcl | 98 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 27 |
| Levetiracetam | Levetiracetam | 82 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 15 |
| Azithromycin | Azithromycin | 78 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 28 |
| Ozempic | Semaglutide | 77 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 11 |
| Alprazolam | Alprazolam | 68 | 22 |
| Finasteride | Finasteride | 67 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 17 |
| Ezetimibe | Ezetimibe | 62 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 25 |
| Risperidone | Risperidone | 60 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 11 |
| Bupropion Xl | Bupropion Hcl | 56 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Glimepiride | Glimepiride | 56 | 18 |
| Trulicity | Dulaglutide | 55 | 11 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 15 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Atenolol | Atenolol | 44 | 17 |
| Cephalexin | Cephalexin | 44 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 12 |
| Allopurinol | Allopurinol | 42 | 20 |
| Ondansetron Odt | Ondansetron | 42 | 18 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 23 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 40 | 11 |
| Celecoxib | Celecoxib | 40 | suppressed |
| Gemtesa | Vibegron | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 11 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 22 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Valsartan | Valsartan | 38 | 12 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Calcitriol | Calcitriol | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 11 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Estradiol | Estradiol | 30 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | 14 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Nystop | Nystatin | 26 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 14 |
| Nystatin | Nystatin | 23 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Klayesta | Nystatin | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Paricalcitol | Paricalcitol | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 12 |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Naproxen | Naproxen | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.94 · 27 records | Amgen Inc. | AIRSUPRA, BOTOX, CAPLYTA, FARXIGA, JARDIANCE, JOURNAVX, NURTEC ODT, OTEZLA, REPATHA, Veozah, Wegovy, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error